GI CANCERS

Latest News

FDA Withdraws Infigratinib Approval for Cholangiocarcinoma
FDA Withdraws Infigratinib Approval for Cholangiocarcinoma

May 20th 2024

The FDA has withdrawn the approval for infigratinib to treat patients with cholangiocarcinoma. A phase 3 study comparing it to standard treatment has also been halted.

Pembrolizumab/Trastuzumab/Chemo Enhances Survival in HER2+ Gastric Cancer
Pembrolizumab/Trastuzumab/Chemo Enhances Survival in HER2+ Gastric Cancer

May 1st 2024

Durvalumab Plus Chemo Continues to Improve Survival in Biliary Tract Cancer
Durvalumab Plus Chemo Continues to Improve Survival in Biliary Tract Cancer

April 16th 2024

KEYNOTE-859 Outcomes Influence NCCN Guidelines on Pembrolizumab in Upper GI Cancer
KEYNOTE-859 Outcomes Influence NCCN Guidelines on Pembrolizumab in Upper GI Cancer

April 10th 2024